Search tips
Search criteria 


Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 2000 May; 108(5): 435–439.
PMCID: PMC1638057
Research Article

Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements.


The presence of blue-green algae (BGA) toxins in surface waters used for drinking water sources and recreation is receiving increasing attention around the world as a public health concern. However, potential risks from exposure to these toxins in contaminated health food products that contain BGA have been largely ignored. BGA products are commonly consumed in the United States, Canada, and Europe for their putative beneficial effects, including increased energy and elevated mood. Many of these products contain Aphanizomenon flos-aquae, a BGA that is harvested from Upper Klamath Lake (UKL) in southern Oregon, where the growth of a toxic BGA, Microcystis aeruginosa, is a regular occurrence. M. aeruginosa produces compounds called microcystins, which are potent hepatotoxins and probable tumor promoters. Because M. aeruginosa coexists with A. flos-aquae, it can be collected inadvertently during the harvesting process, resulting in microcystin contamination of BGA products. In fall 1996, the Oregon Health Division learned that UKL was experiencing an extensive M. aeruginosa bloom, and an advisory was issued recommending against water contact. The advisory prompted calls from consumers of BGA products, who expressed concern about possible contamination of these products with microcystins. In response, the Oregon Health Division and the Oregon Department of Agriculture established a regulatory limit of 1 microg/g for microcystins in BGA-containing products and tested BGA products for the presence of microcystins. Microcystins were detected in 85 of 87 samples tested, with 63 samples (72%) containing concentrations > 1 microg/g. HPLC and ELISA tentatively identified microcystin-LR, the most toxic microcystin variant, as the predominant congener.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Beasley VR, Dahlem AM, Cook WO, Valentine WM, Lovell RA, Hooser SB, Harada K, Suzuki M, Carmichael WW. Diagnostic and clinically important aspects of cyanobacterial (blue-green algae) toxicoses. J Vet Diagn Invest. 1989 Oct;1(4):359–365. [PubMed]
  • Frazier K, Colvin B, Styer E, Hullinger G, Garcia R. Microcystin toxicosis in cattle due to overgrowth of blue-green algae. Vet Hum Toxicol. 1998 Feb;40(1):23–24. [PubMed]
  • Jackson AR, McInnes A, Falconer IR, Runnegar MT. Clinical and pathological changes in sheep experimentally poisoned by the blue-green alga Microcystis aeruginosa. Vet Pathol. 1984 Jan;21(1):102–113. [PubMed]
  • Hunter PR. Cyanobacteria and human health. J Med Microbiol. 1992 May;36(5):301–302. [PubMed]
  • Falconer IR, Beresford AM, Runnegar MT. Evidence of liver damage by toxin from a bloom of the blue-green alga, Microcystis aeruginosa. Med J Aust. 1983 May 28;1(11):511–514. [PubMed]
  • Jochimsen EM, Carmichael WW, An JS, Cardo DM, Cookson ST, Holmes CE, Antunes MB, de Melo Filho DA, Lyra TM, Barreto VS, et al. Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil. N Engl J Med. 1998 Mar 26;338(13):873–878. [PubMed]
  • Carmichael WW. The toxins of cyanobacteria. Sci Am. 1994 Jan;270(1):78–86. [PubMed]
  • Chu FS, Huang X, Wei RD, Carmichael WW. Production and characterization of antibodies against microcystins. Appl Environ Microbiol. 1989 Aug;55(8):1928–1933. [PMC free article] [PubMed]
  • Chu FS, Huang X, Wei RD. Enzyme-linked immunosorbent assay for microcystins in blue-green algal blooms. J Assoc Off Anal Chem. 1990 May-Jun;73(3):451–456. [PubMed]
  • Dourson ML, Felter SP, Robinson D. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul Toxicol Pharmacol. 1996 Oct;24(2 Pt 1):108–120. [PubMed]
  • Fawell JK, Mitchell RE, Everett DJ, Hill RE. The toxicity of cyanobacterial toxins in the mouse: I microcystin-LR. Hum Exp Toxicol. 1999 Mar;18(3):162–167. [PubMed]
  • Falconer IR, Smith JV, Jackson AR, Jones A, Runnegar MT. Oral toxicity of a bloom of the Cyanobacterium microcystis Aeruginosa administered to mice over periods up to 1 year. J Toxicol Environ Health. 1988;24(3):291–305. [PubMed]
  • Yoshida T, Makita Y, Tsutsumi T, Nagata S, Tashiro F, Yoshida F, Sekijima M, Tamura S, Harada T, Maita K, et al. Immunohistochemical localization of microcystin-LR in the liver of mice: a study on the pathogenesis of microcystin-LR-induced hepatotoxicity. Toxicol Pathol. 1998 May-Jun;26(3):411–418. [PubMed]
  • Nishiwaki R, Ohta T, Sueoka E, Suganuma M, Harada K, Watanabe MF, Fujiki H. Two significant aspects of microcystin-LR: specific binding and liver specificity. Cancer Lett. 1994 Aug 15;83(1-2):283–289. [PubMed]
  • Robinson NA, Pace JG, Matson CF, Miura GA, Lawrence WB. Tissue distribution, excretion and hepatic biotransformation of microcystin-LR in mice. J Pharmacol Exp Ther. 1991 Jan;256(1):176–182. [PubMed]
  • Runnegar M, Berndt N, Kong SM, Lee EY, Zhang L. In vivo and in vitro binding of microcystin to protein phosphatases 1 and 2A. Biochem Biophys Res Commun. 1995 Nov 2;216(1):162–169. [PubMed]
  • Nishiwaki-Matsushima R, Ohta T, Nishiwaki S, Suganuma M, Kohyama K, Ishikawa T, Carmichael WW, Fujiki H. Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR. J Cancer Res Clin Oncol. 1992;118(6):420–424. [PubMed]
  • Takai A, Sasaki K, Nagai H, Mieskes G, Isobe M, Isono K, Yasumoto T. Inhibition of specific binding of okadaic acid to protein phosphatase 2A by microcystin-LR, calyculin-A and tautomycin: method of analysis of interactions of tight-binding ligands with target protein. Biochem J. 1995 Mar 15;306(Pt 3):657–665. [PubMed]
  • Ueno Y, Nagata S, Tsutsumi T, Hasegawa A, Watanabe MF, Park HD, Chen GC, Chen G, Yu SZ. Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis. 1996 Jun;17(6):1317–1321. [PubMed]
  • Wu C, Maurer C, Wang Y, Xue S, Davis DL. Water pollution and human health in China. Environ Health Perspect. 1999 Apr;107(4):251–256. [PMC free article] [PubMed]
  • Matthews HB, Lucier GW, Fisher KD. Medicinal herbs in the United States: research needs. Environ Health Perspect. 1999 Oct;107(10):773–778. [PMC free article] [PubMed]
  • Angell M, Kassirer JP. Alternative medicine--the risks of untested and unregulated remedies. N Engl J Med. 1998 Sep 17;339(12):839–841. [PubMed]
  • Taylor D. Herbal medicine at a crossroads. Environ Health Perspect. 1996 Sep;104(9):924–928. [PMC free article] [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science